Invasive Pneumococcal Disease (IPD)

DISEASE BURDEN

Invasive Pneumococcal Disease (IPD)

IPD occurs when Streptococcus pneumoniae invades normally sterile sites in the body, such as the blood or cerebrospinal fluid. IPD can lead to serious illness and hospitalization, and can sometimes be fatal.1

Some adults, including older adults or those with certain chronic medical conditions or immunocompromising conditions, are at increased risk for IPD and its serious, sometimes life-threatening complications.

Serotype 3 and IPD

Over the last decade, serotype 3 has been a significant cause of IPD in adults.2

In fact, serotype 3 is the leading cause of IPD in the United States and contributes to ~15% of cases in adults.3,a

That’s about 1 in 6 cases.

Serotype 3 is the Leading Cause of IPD in the U.S, Contributing to ~15% (1 in 6) Cases in Adults

The thicker polysaccharide capsule of serotype 3 allows bacteria to evade host immune defenses, contributing to its virulence.4

aCDC Active Bacterial Core surveillance data, 2017-2018.3

CDC, Centers for Disease Control and Prevention.

What Does the Immunogenicity Data Show About VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)?

What does the immunogenicity data show about VAXNEUVANCE?

Go to Immunogenicity
ref1

Reference

  1. CDC. Pneumococcal disease. Last reviewed August 18, 2021. Accessed December 16, 2021. www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html

ref2

Reference

  1. CDC. Drug-resistant Streptococcus pneumoniae. Last reviewed March 2, 2021. Accessed December 16, 2021. www.cdc.gov/drugresistance/pdf/threats-report/strep-pneumoniae-508.pdf
ref3

Reference

  1. Pilishvili T, Gierke R, Farley M, et al. Epidemiology of invasive pneumococcal disease (IPD) following 18 years of pneumococcal conjugate vaccine (PCV) use in the United States. Poster presented at: International Symposium on Pneumococcal Diseases; June 21-24, 2020, Toronto, Canada.
ref4

Reference

  1. ACIP. Introduction of the pneumococcal work group. Updated October 28, 2020. Accessed December 16, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/pneumo-01-Poehling-Kobayashi-508.pdf
ref5

Reference

  1. Sugimoto N, Yamagishi Y, Hirai J, et al. Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: A case report and literature review. BMC Res Notes. 2018;10:21. doi:10.1186/s13104-016-2353-3

Indication for VAXNEUVANCE

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information for VAXNEUVANCE

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

The most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection-site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection-site swelling (21.7%), injection-site erythema (15.1%), and arthralgia (12.7%).

The most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection-site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection-site swelling (15.4%), injection-site erythema (10.9%), and arthralgia (7.7%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indication for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

The most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection-site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection-site swelling (21.7%), injection-site erythema (15.1%), and arthralgia (12.7%).

The most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection-site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection-site swelling (15.4%), injection-site erythema (10.9%), and arthralgia (7.7%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.
Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

https://www.vaxelis.com

CANCEL
CONTINUE

Thank you for visiting.

US-PVC-01031 10/22